Ethnic origin has no influence on the pharmacokinetics and pharmaeodynamics of ximelagatran in young, healthy men.

被引：0
|
作者：
Johansson, LC
Frison, L
Nakanishi, T
Fager, G
机构：
[1] AstraZeneca R&D Molndal, Expt Med, Molndal, Sweden
[2] AstraZeneca KK, Osaka, Japan
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3979
引用
收藏
页码：124B / 124B
页数：1
相关论文
共 50 条
  • [1] Comparison of the pharmacokinetics and pharmacodynamics of ximelagatran in young and elderly, healthy Japanese men.
    Johansson, LC
    Nyström, P
    Johnsson, G
    Nakanishi, T
    Eriksson, UG
    [J]. BLOOD, 2002, 100 (11) : 124B - 125B
  • [2] No influence of ethnic origin on the PK and PD properties of ximelagatran in young, healthy males.
    Johansson, LC
    Frison, L
    Nakanishi, T
    Fager, G
    Eriksson, UG
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P22 - P22
  • [3] Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Ximelagatran in Young Healthy Japanese Men
    Linda C. Wernevik
    Per Nyström
    Gillis Johnsson
    Takashi Nakanishi
    Ulf G. Eriksson
    [J]. Clinical Pharmacokinetics, 2006, 45 : 77 - 84
  • [4] Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men
    Wernevik, LC
    Nyström, P
    Johnsson, G
    Nakanishi, T
    Eriksson, UG
    [J]. CLINICAL PHARMACOKINETICS, 2006, 45 (01) : 77 - 84
  • [5] No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor to healthy male volunteers
    Johansson, LC
    Andersson, M
    Fager, G
    Gustafsson, D
    Eriksson, UG
    [J]. CLINICAL PHARMACOKINETICS, 2003, 42 (05) : 475 - 484
  • [6] No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male Volunteers
    Linda C. Johansson
    Magnus Andersson
    Gunnar Fager
    David Gustafsson
    Ulf G. Eriksson
    [J]. Clinical Pharmacokinetics, 2003, 42 : 475 - 484
  • [7] Determinants of augmentation index in healthy young men.
    van Trijp, M
    Uiterwaal, C
    Oren, A
    Bos, WJ
    Grobbee, R
    Bots, M
    [J]. CIRCULATION, 2004, 109 (07) : E117 - E117
  • [8] Regulation of nutrient balance in healthy young and older men.
    Davy, KP
    Horton, TJ
    Davy, BM
    Bessessen, D
    Flanagan, M
    Hill, JO
    [J]. FASEB JOURNAL, 1999, 13 (04): : A374 - A374
  • [9] Pharmacokinetics and excretion balance of OR-1896, a metabolite of levosimendan, in healthy men.
    Puttonen, J.
    Laine, T.
    Hakkinen, S.
    Ramela, M.
    Zhang, W.
    Pradhan, R.
    Pentikainen, P. J.
    Koskinen, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S37 - S37
  • [10] Single dose pharmacokinetics of tomato-based lycopene in healthy men.
    Diwadkar-Navsariwala, V
    Gustin, DM
    Rodvold, KA
    Sosman, JA
    Stacewicz-Sapuntzakis, M
    Murray, JL
    Tiller, PA
    Bowen, PE
    [J]. FASEB JOURNAL, 2001, 15 (04): : A297 - A297
12345